(VIANEWS) – SCYNEXIS (SCYX), Capital Product Partners L.P. (CPLP), Eli Lilly and Company (LLY) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. SCYNEXIS (SCYX)
889.4% sales growth and 132.23% return on equity
SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including recurrent VVC, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections; and ibrexafungerp that has completed Phase 3 CANDLE study for the prevention of recurrent (VVC). It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
Earnings Per Share
As for profitability, SCYNEXIS has a trailing twelve months EPS of $1.49.
PE Ratio
SCYNEXIS has a trailing twelve months price to earnings ratio of 1.33. Meaning, the purchaser of the share is investing $1.33 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 132.23%.
2. Capital Product Partners L.P. (CPLP)
38.3% sales growth and 8.7% return on equity
Capital Product Partners L.P., a shipping company, provides marine transportation services in Greece. Its vessels transports a range of dry cargoes and containerized goods under short-term voyage charters, and medium to long-term time and bareboat charters. As of April 26, 2021, the company owned 17 vessels, including thirteen Neo-Panamax container vessels, three Panamax container vessels, and one Capesize bulk carrier. Capital GP L.L.C. serves as the general partner of the company. The company was incorporated in 2007 and is headquartered in Piraeus, Greece.
Earnings Per Share
As for profitability, Capital Product Partners L.P. has a trailing twelve months EPS of $2.71.
PE Ratio
Capital Product Partners L.P. has a trailing twelve months price to earnings ratio of 6.28. Meaning, the purchaser of the share is investing $6.28 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.7%.
Moving Average
Capital Product Partners L.P.’s value is way above its 50-day moving average of $13.99 and way above its 200-day moving average of $13.93.
Sales Growth
Capital Product Partners L.P.’s sales growth is 19.8% for the current quarter and 38.3% for the next.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter is a negative 38.8% and positive 53.1% for the next.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Capital Product Partners L.P.’s EBITDA is 27.16.
3. Eli Lilly and Company (LLY)
21.6% sales growth and 46.46% return on equity
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; Foghorn Therapeutics Inc., and PRISM BioLab Co.,Ltd. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Earnings Per Share
As for profitability, Eli Lilly and Company has a trailing twelve months EPS of $5.51.
PE Ratio
Eli Lilly and Company has a trailing twelve months price to earnings ratio of 113.82. Meaning, the purchaser of the share is investing $113.82 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 46.46%.
Yearly Top and Bottom Value
Eli Lilly and Company’s stock is valued at $627.15 at 10:22 EST, below its 52-week high of $647.73 and way higher than its 52-week low of $309.20.
Volume
Today’s last reported volume for Eli Lilly and Company is 1879830 which is 40.18% below its average volume of 3142650.
Sales Growth
Eli Lilly and Company’s sales growth is 22.3% for the ongoing quarter and 21.6% for the next.
Revenue Growth
Year-on-year quarterly revenue growth grew by 36.8%, now sitting on 32.07B for the twelve trailing months.
4. Royal Caribbean Cruises (RCL)
17.1% sales growth and 23.71% return on equity
Royal Caribbean Cruises Ltd. operates as a cruise company worldwide. The company operates cruises under the Royal Caribbean International, Celebrity Cruises, and Silversea Cruises brands, which comprise a range of itineraries. As of February 13, 2023, it operated 64 ships. The company was founded in 1968 and is headquartered in Miami, Florida.
Earnings Per Share
As for profitability, Royal Caribbean Cruises has a trailing twelve months EPS of $3.28.
PE Ratio
Royal Caribbean Cruises has a trailing twelve months price to earnings ratio of 38.6. Meaning, the purchaser of the share is investing $38.6 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 23.71%.
Volume
Today’s last reported volume for Royal Caribbean Cruises is 1137090 which is 59.47% below its average volume of 2805680.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Royal Caribbean Cruises’s EBITDA is 25.57.
Sales Growth
Royal Caribbean Cruises’s sales growth is 28.6% for the present quarter and 17.1% for the next.
Previous days news about Royal Caribbean Cruises(RCL)
- According to Zacks on Wednesday, 24 January, "The demand for nonobligatory products and services is expected to pick up, which calls for investing in stocks such as GIII Apparel Group (GIII Quick QuoteGIII – Free Report) , Acushnet (GOLF Quick QuoteGOLF – Free Report) , Hooker Furniture (HOFT Quick QuoteHOFT – Free Report) , Netflix (NFLX Quick QuoteNFLX – Free Report) and Royal Caribbean Cruises (RCL Quick QuoteRCL – Free Report) ."
5. Essent Group Ltd. (ESNT)
14% sales growth and 14.69% return on equity
Essent Group Ltd., through its subsidiaries, provides private mortgage insurance and reinsurance for mortgages secured by residential properties located in the United States. Its mortgage insurance products include primary, pool, and master policy. The company also provides information technology maintenance and development services; customer support-related services; underwriting consulting; and contract underwriting services. It serves the originators of residential mortgage loans, such as regulated depository institutions, mortgage banks, credit unions, and other lenders. The company was founded in 2008 and is based in Hamilton, Bermuda.
Earnings Per Share
As for profitability, Essent Group Ltd. has a trailing twelve months EPS of $6.23.
PE Ratio
Essent Group Ltd. has a trailing twelve months price to earnings ratio of 8.89. Meaning, the purchaser of the share is investing $8.89 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 14.69%.
Sales Growth
Essent Group Ltd.’s sales growth is 24.4% for the present quarter and 14% for the next.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on Nov 29, 2023, the estimated forward annual dividend rate is 1 and the estimated forward annual dividend yield is 1.83%.
Yearly Top and Bottom Value
Essent Group Ltd.’s stock is valued at $55.39 at 10:22 EST, under its 52-week high of $55.99 and way above its 52-week low of $36.53.
6. Fomento Economico Mexicano S.A.B. de C.V. (FMX)
11.8% sales growth and 14.72% return on equity
Fomento Económico Mexicano, S.A.B. de C.V., through its subsidiaries, operates as a bottler of Coca-Cola trademark beverages. The company produces, markets, and distributes Coca-Cola trademark beverages in Mexico, Guatemala, Nicaragua, Costa Rica, Panama, Colombia, Venezuela, Brazil, Argentina, and Uruguay. It also operates small-box retail chain stores in Mexico, Colombia, Peru, Chile, and Brazil under the OXXO name; retail service stations for fuels, motor oils, lubricants, and car care products under the OXXO GAS name in Mexico; and drugstores in Chile, Colombia, Ecuador, and Mexico under the Cruz Verde, Fybeca, SanaSana, YZA, La Moderna, and Farmacon names. In addition, the company is involved in the production and distribution of collers, commercial refrigeration equipment, plastic boxes, food processing, and preservation and weighing equipment; and provision of logistic transportation, distribution and maintenance, point-of-sale refrigeration, and plastics solutions, as well as distribution platform for cleaning products and consumables. Further, it operates small-box retail and food convenience chain stores in Switzerland, Germany, Austria, Luxembourg, and the Netherlands under the k kiosk, Brezelkönig, BackWerk, Ditsch, Press & Books, avec, Caffè Spettacolo, and ok.–) names, as well as pretzels under the Ditsch name. The company was founded in 1890 and is based in Monterrey, Mexico.
Earnings Per Share
As for profitability, Fomento Economico Mexicano S.A.B. de C.V. has a trailing twelve months EPS of $3.97.
PE Ratio
Fomento Economico Mexicano S.A.B. de C.V. has a trailing twelve months price to earnings ratio of 34.12. Meaning, the purchaser of the share is investing $34.12 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 14.72%.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on Nov 2, 2023, the estimated forward annual dividend rate is 2.07 and the estimated forward annual dividend yield is 1.55%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 19.3%, now sitting on 760.87B for the twelve trailing months.
Volume
Today’s last reported volume for Fomento Economico Mexicano S.A.B. de C.V. is 19504 which is 96.28% below its average volume of 525101.
7. HealthStream (HSTM)
6.2% sales growth and 3.89% return on equity
HealthStream, Inc. provides workforce and provider solutions for healthcare organizations in the United States. It operates through two segments, Workforce Solutions and Provider Solutions. The company offers workforce solutions, including software-as-a-service (SaaS) based services and subscription-based solutions to meet the range of its clinical development, talent management, training, certification, scheduling, competency assessment, performance appraisal, and other needs, as well as implementation and account management services. It also provides applications for learning, compensation management, succession planning, competency management, disclosure management, simulation-based education, quality management, and industry training. In addition, the company offers VerityStream that delivers enterprise-class solutions to transform the healthcare provider experience for ambulatory surgery centers, urgent care facilities, clinics, medical groups, and other healthcare organizations; EchoCredentialing and MSOW platforms that manage medical staff credentialing, enrollment, and privileging processes for hospitals; and EchoOneApp, a provider enrollment platform for medical groups. Further, it provides CredentialMyDoc, a credentialing and enrollment SaaS solution for medical groups and surgery centers; CredentialStream, a SaaS-based provider credentialing, privileging, and enrollment solution; and NurseGrid Mobile for nurse managers. The company offers its solutions in healthcare industry companies that include private, not-for-profit, and government entities, as well as pharmaceutical and medical device companies through direct sales teams. HealthStream, Inc. was incorporated in 1990 and is headquartered in Nashville, Tennessee.
Earnings Per Share
As for profitability, HealthStream has a trailing twelve months EPS of $0.43.
PE Ratio
HealthStream has a trailing twelve months price to earnings ratio of 62.84. Meaning, the purchaser of the share is investing $62.84 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 3.89%.
Yearly Top and Bottom Value
HealthStream’s stock is valued at $27.02 at 10:22 EST, below its 52-week high of $27.69 and way higher than its 52-week low of $20.47.
Revenue Growth
Year-on-year quarterly revenue growth grew by 4.5%, now sitting on 277.02M for the twelve trailing months.
Volume
Today’s last reported volume for HealthStream is 60761 which is 48.05% below its average volume of 116977.
Moving Average
HealthStream’s worth is higher than its 50-day moving average of $25.98 and way above its 200-day moving average of $24.07.
8. PetIQ (PETQ)
5.6% sales growth and 5.68% return on equity
PetIQ, Inc. operates as a pet medication and wellness company in the United States and internationally. It operates in two segments, Products and Services. The company offers Rx pet medications, which include flea and tick control, heartworm preventatives, arthritis, thyroid, diabetes and pain treatments, antibiotics, and other specialty medications; and develops and manufactures its own proprietary value-branded products, as well as distributes third-party branded medications. It also provides OTC medications and supplies primarily within the flea and tick control, and behavior management categories of the health and wellness industry in various forms, such as spot on (topical) treatments, chewables, oral tablets, and collars. In addition, the company offers health and wellness products that include dental treats and nutritional supplements, which comprise hip and joint, vitamins, and skin and coat products. The company provides its products primarily under the PetIQ, PetArmor, VIP Petcare, VetIQ PetCare, VetIQ, Capstar, Advecta, SENTRY, Sergeants, PetLock, Heart Shield Plus, TruProfen, Betsy Farms, PetAction, Minties, Vera, and Delightibles brands. In addition, the company offers a suite of services at community clinics and wellness centers hosted at pet retailers, including diagnostic tests, vaccinations, prescription medications, microchipping, and wellness checks. It operates through veterinarian, retail, and e-commerce channels. The company was founded in 2010 and is headquartered in Eagle, Idaho.
Earnings Per Share
As for profitability, PetIQ has a trailing twelve months EPS of $0.44.
PE Ratio
PetIQ has a trailing twelve months price to earnings ratio of 41.14. Meaning, the purchaser of the share is investing $41.14 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.68%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 32.1%, now sitting on 1.07B for the twelve trailing months.
Earnings Before Interest, Taxes, Depreciation, and Amortization
PetIQ’s EBITDA is 37.93.
Volume
Today’s last reported volume for PetIQ is 185949 which is 38.54% below its average volume of 302570.
Sales Growth
PetIQ’s sales growth is 2.7% for the current quarter and 5.6% for the next.
